Core Viewpoint - The company 康为世纪 (688426.SH) expects to reduce its net loss for the year 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -1.12 billion to -914.41 million, reflecting a year-on-year reduction in loss of 28.91% to 41.83% [1] Financial Performance - The projected net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to range from -1.43 billion to -1.23 billion, indicating a year-on-year reduction in loss of 20.64% to 31.90% [1] - The main reason for the performance change is attributed to the recovery phase of the life sciences and diagnostic reagent industry, along with the ongoing market expansion of new businesses that have not yet achieved economies of scale [1] Revenue Growth - The reduction in net loss is primarily due to an increase in main business revenue, with significant overall sales revenue growth during the reporting period [1] - The growth is mainly driven by the rapid expansion of the company's technology service businesses, including gene sequencing and gene synthesis [1]

Core Viewpoint - The company 康为世纪 (688426.SH) expects to reduce its net loss for the year 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -1.12 billion to -914.41 million, reflecting a year-on-year reduction in loss of 28.91% to 41.83 [1] Financial Performance - The projected net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to range from -1.43 billion to -1.23 billion, indicating a year-on-year reduction in loss of 20.64% to 31.90% [1] - The main reason for the change in performance is attributed to the recovery phase of the life sciences and diagnostic reagent industry, along with the ongoing market expansion of new business which has not yet achieved economies of scale [1] Revenue Growth - The reduction in net loss is primarily due to an increase in main business revenue, with significant overall sales revenue growth during the reporting period [1] - The growth is mainly driven by the rapid expansion of the company's technology service businesses, including gene sequencing and gene synthesis [1]

Group 1 - The company Jiangsu Kangwei Century Biotechnology Co., Ltd. expects to reduce its net loss for the year 2025, projecting a net profit attributable to the parent company of approximately -112 million to -91.44 million yuan, representing a year-on-year reduction in loss of 28.91% to 41.83% [1] - The primary reason for the performance change is that the life sciences and diagnostic reagent industry is in a recovery phase [1] - The company is expanding into new business areas, which have not yet achieved economies of scale [1]

Core Viewpoint - The company expects a reduction in net loss for the fiscal year 2025, with projections indicating a net profit attributable to the parent company ranging from -111.76 million to -91.44 million, representing a year-on-year decrease in loss of 28.91% to 41.83 [1] Financial Performance - The projected non-GAAP net profit is expected to be between -143.30 million and -122.98 million, showing a year-on-year decrease in loss of 20.64% to 31.90% [1] - The previous year's net profit attributable to the parent company was -157.21 million, and the non-GAAP net profit was -180.57 million [1] Industry Context - The primary reason for the ongoing losses is that the life sciences and diagnostic reagents industry is in a recovery phase, and new business ventures have not yet achieved economies of scale [1] - The reduction in net profit loss is attributed to an increase in main business revenue and rapid growth in technology service operations [1]